PP-101

**PP-101** was Prismic Pharmaceuticals' and subsequently FSD Pharma's investigational oral micro-palmitoylethanolamide formulation, developed as a non-opioid, anti-inflammatory and analgesic candidate for fibromyalgia. It was described as a 600 mg micro-PEA tablet intended for use concomitantly with pregabalin rather than as a confirmed fixed-dose co-formulation. Palmitoylethanolamide is an endogenous N-acylethanolamine lipid mediator whose principal pharmacology is activation of peroxisome proliferator-activated receptor alpha, with additional evidence for transient receptor potential cation channel subfamily V member 1 modulation. FSD initiated a Phase 1 first-in-human safety and tolerability study of PP-101 micro-PEA in Australia in 2020. ([marketscreener.com](https://www.marketscreener.com/quote/stock/QUANTUM-BIOPHARMA-LTD-43536373/news/FSD-Pharma-Closes-Deal-to-Acquire-Prismic-Pharmaceuticals-28842207/))

Other names

micro-palmitoylethanolamidemicro-PEA